FDA Opens Investigation Into Ozempic and Eye Condition Reports
The U.S. Food and Drug Administration announced on Friday that it has opened a formal investigation into reports connecting semaglutide, marketed as Ozempic and Wegovy, to a rare eye condition known as non-arteritic anterior ischemic optic neuropathy (NAION). The condition, which can cause sudden and sometimes permanent vision loss, has been reported by a growing number of patients using the blockbuster medication.
According to the FDA's adverse event reporting system, more than 140 cases of suspected NAION have been filed since January 2025, a significant increase from the baseline rate seen in the general population. While the agency emphasized that a causal link has not been established, the volume of reports has prompted a closer look at the potential relationship between GLP-1 receptor agonists and ocular health.
What Is NAION and Why Is It Concerning?
NAION occurs when blood flow to the optic nerve is suddenly reduced, leading to swelling and damage. Symptoms typically include:
- Sudden, painless loss of vision in one eye
- Blurred or dimmed vision upon waking
- Loss of the upper or lower half of the visual field
- Difficulty perceiving contrast and colors
The condition is the most common cause of sudden optic nerve-related vision loss in adults over 50, affecting roughly 2 to 10 per 100,000 people annually. However, researchers at Harvard Medical School published a study in September 2025 suggesting that patients on semaglutide may face a risk up to seven times higher than the general population.
"We are not telling patients to stop their medication, but we are urging both patients and physicians to be vigilant about any changes in vision," said Dr. Joseph Rizzo, a neuro-ophthalmologist at Massachusetts Eye and Ear and lead author of the Harvard study.
How Novo Nordisk Has Responded
Novo Nordisk, the Danish pharmaceutical company that manufactures Ozempic, issued a statement acknowledging the FDA's investigation and reaffirming its commitment to patient safety. The company noted that millions of patients worldwide use semaglutide-based medications and that the overall safety profile remains favorable.
"Patient safety is our top priority," the company said. "We are cooperating fully with the FDA and are conducting our own post-marketing surveillance analysis. At this time, we believe the benefits of semaglutide continue to outweigh the risks for approved indications."
The company has not issued any label changes or warnings related to NAION, though analysts expect the FDA may require updated prescribing information depending on the investigation's findings.
What Patients Should Do Right Now
Medical professionals are advising patients currently taking Ozempic, Wegovy, or any other semaglutide-based medication to take the following precautions:
- Do not stop taking your medication without consulting your doctor first
- Schedule a baseline eye exam if you have not had one recently
- Report any sudden vision changes to your healthcare provider immediately
- Be aware of risk factors including diabetes, hypertension, sleep apnea, and a small optic disc
The American Academy of Ophthalmology released guidance this week recommending that prescribers discuss the potential ocular risks with patients before initiating GLP-1 therapy, particularly those with pre-existing eye conditions or cardiovascular risk factors.
The Broader Implications for GLP-1 Medications
This investigation arrives at a critical moment for the GLP-1 drug class, which has become one of the most prescribed categories of medication in the United States. Ozempic and Wegovy generated more than $21 billion in global revenue for Novo Nordisk in 2025, and competitors including Eli Lilly's Mounjaro and Zepbound have similarly surged in popularity.
Any safety signal that leads to label changes or prescribing restrictions could have significant implications for the broader weight-loss and diabetes treatment landscape. Wall Street analysts noted that Novo Nordisk shares dipped 3.2% in early trading following the FDA announcement, though the stock recovered somewhat by midday.
The FDA said it expects to provide an update on its findings by the end of the second quarter of 2026. In the meantime, healthcare providers are encouraged to report any suspected cases of NAION in semaglutide users through the agency's MedWatch program.
